Triple therapy AMD trial to continue

Article

The Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) is to continue as planned, following promising interim results and the positive recommendations of the independent Data and Safety Monitoring Committee.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
Two elderly patients, a black woman and a white man, in a clinic support each other. Image credit: ©Seventyfour – stock.adobe.com

UK audit explores reasons patients skip diabetic retinopathy screenings

Lynda Charters
January 2nd 2025
Article

Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The number 2024 in big red-and-yellow text, on a backdrop of eye illustrations. Image created in Canva.

Ophthalmology Times wraps up a year of innovation and insight

Martin David Harp
December 30th 2024
Article

Highlights from the year, courtesy of our colleagues at Ophthalmology Times

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Calendar pages for 2024 are peeling away, replaced by pages for 2024. The message below reads, "We wish you a happy new year." Image credit: ©simbos – stock.adobe.com

Looking back at 2024 with our colleagues from Optometry Times

Emily Kaiser Maharjan
December 27th 2024
Article

The top therapeutic advancements in myopia, diabetes, dry eye and more

The number 2024 in shiny mylar balloons, on a backdrop of confetti, balloons and streamers. Image created with Canva AI.

Wrapping up another year in eye care: 2024 in review

Hattie Hayes
December 26th 2024
Article

Trending topics and milestone stories from our year in ophthalmology

© 2025 MJH Life Sciences

All rights reserved.